idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
Conditions
Interventions
Subcutaneous administration of etanercept, 0.4 mg/kg (max 25 mg) 2 times a week for four weeks.
Sponsors
Univesity of Tokyo Hospital, Department of Hematology and Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who have received allogeneic hematopoietic stem cell transplantation. (2) Patients with IPS. NIH criteria for IPS (a) multilobar infiltrates on CXR or CT. (b) Clinical signs of pneumonia: cough, dyspnea, or rales. (c) Abnormal physiology: increased arterial-alveolar oxygen gradient, or the need for supplemental oxygen support. (d) Negative BAL for bacterial and nonbacterial organisms. (e) Negative surgical lung biopsy. (a), (b) and (c) were all fulfilled and (d) or (e) was also fulfilled. (3) patients equal or older than 20 yo. (4) written informed consent was obtained.
Exclusion criteria
Exclusion criteria: (1) patients without enough . (2) the presence of any of the following after at the time of enrollment. (a) an active pulmonary infection as determined by positive culture of bronchoalveolar lavage (BAL) fluid. (b) hypotension in which inotropic support other than dopamine was required. (c) bacteremia within 48 hours before study entry. (d) CMV viremia. (e) systemic fungal or other nonbacterial infections. (f) clinical or echocardiographic evidence for cardiac dysfunction as the cause of respiratory failure. (3) pregnancy or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| withdrawal rate from oxygenation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year overall survival | — |
Countries
Japan
Contacts
Public ContactAkira Honda
Univesity of Tokyo Hospital Hematology and Oncology
Outcome results
None listed